New symptoms, conditions may develop after positive test for SARS-CoV-2
Feb 11, 2022
Among hospitalized patients aged 20 years or older, the prevalence of new fatigue and type 2 diabetes were up for those with a positive versus a negative SARS-CoV-2 result.
Capital Senior Living makes moves to improve financial position
By
Lois A. Bowers
Aug 07, 2020
Capital Senior Living plans to transfer operations and ownership of 18 senior living communities to Fannie Mae, the company announced Thursday. The move follows several steps Capital announced in May “to...
$1.9 trillion stimulus plan may not go far enough for senior living, leaders say
By
Kimberly Bonvissuto
Jan 19, 2021
President-elect Joe Biden’s $1.9 trillion coronavirus rescue plan, unveiled Thursday evening, includes an initiative to “protect vulnerable populations in congregate settings,” but it may not go...
Current, recent SARS-CoV-2 infection may up VTE risk after surgery
Aug 26, 2021
A substudy of prospective cohort study shows a link between SARS-CoV-2 infection and an increased risk for postoperative venous thromboembolism.
EHR data support reported effectiveness of Ad26.COV2.S vaccine
Nov 02, 2021
The effectiveness of the Johnson & Johnson Ad26.COV2.S vaccine is 73.6% for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study published online Nov....
Antibody levels high with COVID-19 vaccination for previously infected
Aug 06, 2021
Antibody levels were higher in the previously infected versus infection-naive after one dose of BNT162b2 vaccine.
Senior living occupancy reaches new record low of 78.8 percent in first quarter: NIC
By
Lois A. Bowers
Apr 08, 2021
Occupancy at U.S. senior living communities — independent living and assisted living combined — reached a record low of 78.8% in the first quarter, according to new NIC MAP data released today. The...
mRNA-1273, BNT162b2 vaccines comparable for lowering COVID-19 risk
Dec 02, 2021
The mRNA-1273 vaccine (Moderna) was marginally more effective than the BNT162b2 vaccine (Pfizer-BioNTech) among U.S. veterans, but the risk for outcomes at 24 weeks was low with both vaccines.
FDA authorizes Pfizer, Moderna COVID-19 vaccine boosters for all adults
By
Lois A. Bowers
Nov 19, 2021
The U.S. Food and Drug Administration on Friday amended the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines, authorizing use of a single booster dose for everyone...
Parkinson: Skilled nursing still amid business nightmare
By
Amy Novotney
Feb 03, 2021
As COVID-19 vaccines continue to be rolled out at skilled nursing facilities and assisted living communities nationwide, the “clinical nightmare” soon will be in the long-term care industry’s rearview...